Compare PBT & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBT | KALV |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | PBT | KALV |
|---|---|---|
| Price | $21.37 | $20.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.60 |
| AVG Volume (30 Days) | 153.9K | ★ 1.1M |
| Earning Date | 03-13-2026 | 05-09-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | N/A | $187.19 |
| Revenue Next Year | N/A | $54.93 |
| P/E Ratio | $57.37 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $9.37 | $9.83 |
| 52 Week High | $22.71 | $21.31 |
| Indicator | PBT | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 63.23 |
| Support Level | $19.81 | $14.66 |
| Resistance Level | $22.71 | $21.31 |
| Average True Range (ATR) | 0.91 | 1.37 |
| MACD | -0.11 | 0.04 |
| Stochastic Oscillator | 46.63 | 82.01 |
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.